185 related articles for article (PubMed ID: 34671433)
1. Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment.
Sueta A; Fujiki Y; Goto-Yamaguchi L; Tomiguchi M; Yamamoto-Ibusuki M; Iwase H; Yamamoto Y
Oncol Lett; 2021 Dec; 22(6):819. PubMed ID: 34671433
[TBL] [Abstract][Full Text] [Related]
2. Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.
Stevic I; Müller V; Weber K; Fasching PA; Karn T; Marmé F; Schem C; Stickeler E; Denkert C; van Mackelenbergh M; Salat C; Schneeweiss A; Pantel K; Loibl S; Untch M; Schwarzenbach H
BMC Med; 2018 Oct; 16(1):179. PubMed ID: 30301470
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
4. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
5. Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer.
Todorova VK; Byrum SD; Gies AJ; Haynie C; Smith H; Reyna NS; Makhoul I
Curr Oncol; 2022 Jan; 29(2):613-630. PubMed ID: 35200555
[TBL] [Abstract][Full Text] [Related]
6. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence.
Sueta A; Yamamoto Y; Tomiguchi M; Takeshita T; Yamamoto-Ibusuki M; Iwase H
Oncotarget; 2017 Sep; 8(41):69934-69944. PubMed ID: 29050253
[TBL] [Abstract][Full Text] [Related]
8. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.
Shin VY; Siu JM; Cheuk I; Ng EK; Kwong A
Br J Cancer; 2015 May; 112(11):1751-9. PubMed ID: 25906045
[TBL] [Abstract][Full Text] [Related]
9. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
[No Abstract] [Full Text] [Related]
10. Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing.
Wu H; Wang Q; Zhong H; Li L; Zhang Q; Huang Q; Yu Z
Oncol Rep; 2020 Jan; 43(1):240-250. PubMed ID: 31746410
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling.
Chen J; Chen Z; Huang J; Chen F; Ye W; Ding G; Wang X
Oncol Lett; 2018 Mar; 15(3):3017-3023. PubMed ID: 29435032
[TBL] [Abstract][Full Text] [Related]
12. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.
Cao D; Cao X; Jiang Y; Xu J; Zheng Y; Kang D; Xu C
Hematol Oncol; 2022 Apr; 40(2):172-180. PubMed ID: 34874565
[TBL] [Abstract][Full Text] [Related]
13. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
Hong HC; Chuang CH; Huang WC; Weng SL; Chen CH; Chang KH; Liao KW; Huang HD
Theranostics; 2020; 10(19):8771-8789. PubMed ID: 32754277
[No Abstract] [Full Text] [Related]
14. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
[TBL] [Abstract][Full Text] [Related]
15. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
17. Serum Exosomal MicroRNAs as Potential Circulating Biomarkers for Endometriosis.
Zhang L; Li H; Yuan M; Li D; Sun C; Wang G
Dis Markers; 2020; 2020():2456340. PubMed ID: 32076458
[TBL] [Abstract][Full Text] [Related]
18. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Zheng T; Pang Z; Zhao Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
[TBL] [Abstract][Full Text] [Related]
19. Down Regulated Expression Levels of miR-27b and miR-451a as a Potential Biomarker for Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy.
Abdul Aziz AA; Md Salleh MS; Yahya MM; Zakaria AD; Ankathil R
Asian Pac J Cancer Prev; 2022 Mar; 23(3):1053-1059. PubMed ID: 35345380
[TBL] [Abstract][Full Text] [Related]
20. Revolutionizing treatment for triple-negative breast cancer: Harnessing the power of exosomal miRNAs for targeted therapy.
Jalil AT; Jehad MT; Al-Ameer LR; Khallawi AQ; Essa IM; Merza MS; Zabibah RS; Al-Hili F
Pathol Res Pract; 2023 Oct; 250():154825. PubMed ID: 37769396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
